1 option
AMPK-S6K1 signaling pathway as a target for treating hepatic insulin resistance / Sang Geon Kim, Il Je Cho and Hee Yeon Kay.
- Format:
- Book
- Author/Creator:
- Kim, Sang Geon.
- Series:
- Hepatology research and clinical developments series.
- Hepatology research and clinical developments series
- Language:
- English
- Subjects (All):
- Insulin resistance--Molecular aspecsts.
- Insulin resistance.
- Liver--Diseases--Molecular aspecsts.
- Liver.
- Protein kinases.
- Physical Description:
- 1 online resource (69 p.)
- Edition:
- 1st ed.
- Place of Publication:
- New York : Nova Science Publishers, c2010.
- Language Note:
- English
- Summary:
- Hepatic insulin resistance and altered insulin metabolism, as characterized by the desensitization of hepatic parenchymal cells to insulin, play a role in the pathogenesis of liver disease, particularly resulting in steatosis and steatohepatitis. By the same token, type II diabetic patients are at higher risk for developing liver diseases, including steatosis, hepatitis, cirrhosis, and hepatocellular carcinoma. On the other hand, established liver disease from any cause leads to glucose intolerance and peripheral insulin resistance systemically. The link between insulin resistance and liver pathology reviewed in this book suggests that insulin resistance is closely related with a variety of liver diseases. Recent evidence indicates that the AMP activating protein kinase (AMPK) in conjunction with p70 ribosomal S6 kinase 1 (S6K1) serves as a key signaling pathway regulating insulin-dependent physiological functions; thus, this pathway serves as a target for the therapy of diseases associated with insulin resistance. In this chapter, the regulatory role of the AMPK-S6K1 pathway is discussed in terms of enhancing insulin receptor signaling with insulin receptor substrate-1/2 and phosphatidylinositol phosphate kinase activity, which may contribute to preventing and/or treating insulin resistance in the liver.
- Contents:
- Introduction: Insulin signaling in hepatocytes
- Clinical and preclinical drugs for the treatment of hepatic insulin resistance.
- Notes:
- Description based upon print version of record.
- Includes bibliographical references (p. [33]-49) and index.
- Description based on print version record and CIP data provided by publisher.
- ISBN:
- 1-61761-457-2
- OCLC:
- 830627853
The Penn Libraries is committed to describing library materials using current, accurate, and responsible language. If you discover outdated or inaccurate language, please fill out this feedback form to report it and suggest alternative language.